Biography
Sharon Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies Inc. (ITI) from June 2002 until its acquisition by Johnson & Johnson (JNJ) for $14.6 billion in 2025. Intra-Cellular Therapies focused on developing medicines for mental health disorders like bipolar disorder, depression and schizophrenia and received U.S. Food and Drug Administration (FDA) approval for its novel antipsychotic CAPLYTA® in 2019. She has served on several not-for-profit boards and is also a director of Medincell, a biopharmaceutical company in France (Euronext: MEDCL) and NASDAQ listed Benitec (BNTC). Dr. Mates received a B.S. from Ohio State University, a Ph.D. from the University of Washington and completed her postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School.